The Conversation (0)
Predictive Technology Group Announces Name Change of Its Subsidiary LifeCode Genetics to Predictive Diagnostics
Jun. 02, 2016 08:06AM PST
Genetics InvestingSALT LAKE CITY, UT–(Marketwired – June 02, 2016) – Predictive Technology Group, Inc. (OTC PINK: PRED) announced today that LifeCode Genetics, a wholly-owned subsidiary of Predictive Technology Group, Inc., is changing its name to Predictive Diagnostics. Bradley Robinson, President, Predictive Technology Group, Inc., states, “the name change of LifeCode Genetics to Predictive Diagnostics is to align …
SALT LAKE CITY, UT–(Marketwired – June 02, 2016) – Predictive Technology Group, Inc. (OTC PINK: PRED) announced today that LifeCode Genetics, a wholly-owned subsidiary of Predictive Technology Group, Inc., is changing its name to Predictive Diagnostics.
Bradley Robinson, President, Predictive Technology Group, Inc., states, “the name change of LifeCode Genetics to Predictive Diagnostics is to align its mission and branding in preparation for commercialization of its initial diagnostic.”
About Predictive Technology Group, Inc.
Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of severe and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and acquires proprietary technologies that open windows into the origin of human illness and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to prevent and treat diseases effectively, www.predictivetechnologygroup.com and www.predrx.com.
For further information, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090 and yes@yesinternational.com and info@predicitivetechnologygroup.com.
Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
Image Available: https://www.marketwire.com/library/MwGo/2016/6/2/11G101094/Images/dnapic-dfe9be1235a8836396d1f1ceeef59ef3.jpg
Bradley Robinson, President, Predictive Technology Group, Inc., states, “the name change of LifeCode Genetics to Predictive Diagnostics is to align its mission and branding in preparation for commercialization of its initial diagnostic.”
About Predictive Technology Group, Inc.
Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of severe and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and acquires proprietary technologies that open windows into the origin of human illness and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to prevent and treat diseases effectively, www.predictivetechnologygroup.com and www.predrx.com.
For further information, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090 and yes@yesinternational.com and info@predicitivetechnologygroup.com.
Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
Image Available: https://www.marketwire.com/library/MwGo/2016/6/2/11G101094/Images/dnapic-dfe9be1235a8836396d1f1ceeef59ef3.jpg